DAFTAR PUSTAKA 1. Bakta IM. Hematologi Klinik Ringkas Jakarta : EGC, 2006. 2. Cardama AQ, Cortes JE.

Chronic Myeloid Leukemia: Diagnosis and Treatment. July 2006;81(7):973-988

3. Brien S, Berman E, Borghaei H, DeAngelo D, Devetten and Devine S et al.

Chronic Myelogenous Leukemia; Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. October 2009; 9(7): 954-1023 4. Anonymous. Buku Ajar Ilmu Pnyakit Dalam Jilid II Edisi IV. FK UI; Jakarta. 2006. 5. Anonymous. Chronic Myeloid Leukemia. www.novartisoncology.com. 2007 yang diakses tanggal 13 September 2011.
6. Baccarani M, Dreyling M. Chronic Myeloid Leukemia: ESMO Clinical Practice Guidelines For Diagnosis, Treatment and Follow-up. Ann Oncol (2010)21(suppl 5):v165-v167 7. Au, Caguioa, Cuah, Hsu, Jootar. Chonic Myeloid Leukemia in Asia. Int J Hematol. 2009 Jan;89(1):14-23.

8. Au WY, Caguioa PB, Chuah C, Hu SC, Jootar S, Kim DW, et al. Chronic Myeloud Leukemia in Asia. Int J Hematol (2009) 89: 14-23
9. Cortes JE, Silver RT, Kantarjian H. Cancer management: 13 th Edition; Chronic Myeloid Leukemia. Maret 2011 10.Meng CY. Cytogenetics and Molecular Studies in Chronic Myeloid Leukemia. St Clements University. 2001 11.http://www.mayoclinic.com/health/medical/IM03579 mengenai kromosom Philadelphia , yang diakses 15 September 2011 12. Van Etten RA. Studying the pathogenesis of BCR-ABL+ leukemia in mice.

Oncogene (2002) 21, 8643-8651.

13. Goldman JM, Melo JV. Chronic Myeloid Leukemia-Advances in Biology and

New Approaches to Treatment.N Engl J Med 2003; 349:1451-1464

14. Hehlmann R, Saussele S.Integration of Leukemia Research in Europe: The

Paradigm CML. Haematologica (2008)Vol 93, Issue 12, 1765-1769

15. Meng CY. Cytogenetics and Molecular Studies in Chronic Myeloid

Leukemia. St Clements University. 2001

16.Antolic AR,Zadro R, Sertic D, Labar B. Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction. Biochemia Medica 2009;19(1):63-72.

17. Mughal TI, Goldman JL. Chronic Myeloid Leukemia: Why Does it Evolve FromChronic Phase to Blast Transformation?. Frontiers in Bioscience (2006); 11: 198-208.
18. Fernandez, P.MR. recent advances in cancer research. Highlights of the 92nd

annual meeting of the American Association for Cancer Research; held March 24-28, 2001, in New Orleans, LA, U.S.A. Drugs Today 2001, 37(7): 485
19. Ren R. Mechanisms of BCR-ABL in the Pathogenesis of Chronic

Myelogenous Leukemia. Nat Rev Cancer. 2005;5(3):172-183

20.www.novartisoncology.com. Mengenai Chronic Myeloid Leukemia yang diakses 16 September 2011. 21. Cortes JE, Silver RT, Kantarjian H. Cancer management: 13th Edition;

Chronic Myeloid Leukemia. Maret 2011

22.http://www.cml-info.com. About CML yang diakses 16 September 2011 23.http://sllcanada.org. Chronic Myelogenous Leukemia. The leukemia & Lymphoma Society of Canada. Fighting Blood Cancer. 2010 24.http://www.morphostlab.com/medicoprogramming/sokalscore.html. Sokal Scrore. 2010 25. Hehlmann R, Sauele S. Integration of leukemia research in Europe: the

paradigm CML. Cell Ther Transplant. 2008; 1(2). 86-92

26. Shah NP, Kantarjian H, Kim DW, Rea D, Dorlhiac PE, Milone JH et al.

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia.Journal of Clinical Oncology, Vol

26, No 19 (July 1), 2008: pp. 3204-3212

27.www.eutos.org/content/home/news/.../PocketCard_2010_final.pdf Mengenai Recommendations from the European LeukemiaNet for the Management of chronic myeloid leukemia (CML) yang diakses 19 September 2011

28. Proposal For The Inclusion Of Hydroxyurea In The WHO Model List Of Essential Medicines. 17th Expert Committee on the Selection and Use of Essential Medicines; Geneva. 2009
29.Tarumoto T, Imagawa S, Hotta T, Ohmine K, Nagai T, Takatoku M. A Case of Bilateral Heel Ulcers Associated with Hydroxyurea Therapy for Chronic Myellogenous Leukemia. Jpn J Clin Oncol 2000;30(3) 159-162